Share this article Share this article PHOENIX, Jan. 6, 2021 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ) commented today on a peer-reviewed publication from the University of Miami demonstrating that the intravenous administration of umbilical cord derived stem cells, termed "JadiCells" results in a significant survival improvement in COVID-19 patients. The Phase 1/2 double blind, placebo-controlled trial treated 12 advanced COVID-19 patients with 100 million JadiCells™ intravenously at days 0 and 3, and 12 additional patients received placebo control. At 28 days 91% of JadiCell™ treated patients survived whereas only 42% of patients in the placebo group survived. There were no adverse effects associated with JadiCell™ administration. "The ImmCelz® regenerative immunotherapy product is a personalized cellular therapy generated by co-culture of patient's immune cells with stem cells. Due to the superior nature of the JadiCell™ to other cell types, under license, we exclusively use this cell type for production of ImmCelz®," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings. "The data reported today strongly supports the safety and potency of the JadiCell™, which also supports the validity of ImmCelz® which is 'powered by JadiCell™.'